An observational study in Non-obstructive Coronary Disease and Acute or Chronic Coronary Artery Disease, sponsored by AngioInsight. Enrolling by invitation at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by AngioInsight · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Microvascular Angina with a site in United States — 6 open to participants now, 8 under way, 1 of them phase 3. Microvascular Angina · United States.
Among the 22 studies in Microvascular Angina with a site in United States, this one is one of 2 that started in 2026, is one of 10 observational ones, and was the 21st registered.
111 studies on the registry are indexed under Microvascular Angina; 38 are open to participants now.
Browse Microvascular Angina studies →6 of the 22 studies in Microvascular Angina with a site in United States are open now. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18+ · Women only
Stanford University · Sites in United States
Ages 18+
University of California, Los Angeles · Sites in United States
Ages 18+
University of California, Los Angeles · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Microvascular Angina studies recruiting now, 17 (63%) set no upper age limit and 3 (11%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 1 · Phase 4 2
First in 1992; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 620 is above the median of 200 across 46 observational studies indexed under Microvascular Angina.
Median enrollment 33 across the 12 interventional studies, 136 across the 9 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 22 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with AngioInsight as lead sponsor.
AngioInsight has 1 study filed under Microvascular Angina — fewer than ten, so there is no comparison to draw.
4 of the studies in Microvascular Angina with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06424834Phase 3Stanford UniversityEfficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries | 2026-12 |
| NCT07761728University of California, Los AngelesThe FLARE (Flurpiridaz vs. Rubidium Evaluation) Trial | 2026-12 |
| NCT05913999University of California, Los AngelesSerial PET MPI in Patients Undergoing Cancer Treatment | 2027-07-31 |
| NCT06600178University of VirginiaStudy Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG) | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 22 studies in Microvascular Angina with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to establish the diagnostic performance of the AngioAI+ System (AngioInsight, Inc, USA) for estimating:
SMARTFLOW is a prospective, single-arm, observational multicenter study of patients with suspected coronary artery disease (CAD) undergoing clinically indicated invasive coronary angiography with physiological assessment. The study is designed to prospectively enroll patient cohorts and collect data according to their reference procedures (e.g. FFR, CFR measures). A core lab will evaluate performance of the AngioAI+ software retrospectively using the collected SMARTFLOW study data. As such, the investigational AngioAI+ device will not inform clinical decisions amid the study procedure.
All patients will undergo clinically indicated invasive coronary angiography with physiological assessment according to standard of care.
Cohort 1: Patients with intermediate lesions (30-90% diameter stenosis) will undergo invasive FFR assessment. In patients with FFR >0.80 (non-flow limiting stenosis), subsequent assessment of the microcirculation with bolus and continuous thermodilution will be performed.
Cohort 2: Patients with non-obstructive (\<30% stenosis) disease will undergo assessment of the microcirculation with bolus and continuous thermodilution.
For patients in Cohort 1 with FFR ≤0.80 undergoing percutaneous coronary interventions (PCI), FFR measurements after PCI will be recommended. Use of intravascular imaging will be strongly encouraged to guide PCI procedures, in accordance with current practice guidelines.
Patients with acute or chronic coronary artery disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Angiographic Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with intermediate coronary artery stenosis with clinically indicated invasive FFR assessment
Procedure: Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment.
Symptomatic patients with non-obstructive coronary artery disease (NOCAD) with clinical indication for invasive coronary microvascular assessment
Procedure: Microvascular assessment
Cohort 1. Patients with intermediate coronary artery stenosis (30-90% diameter stenosis) with clinically indicated FFR assessment.
Cohort 2: Patients with non-obstructive (\<30% stenosis) disease will undergo assessment of the microcirculation with bolus and continuous thermodilution.
To establish the diagnostic performance of the AngioAI+ System
1\. Per-vessel diagnostic performance (i.e., sensitivity and specificity) of AngioAI+ FFR for identifying flow-limiting lesions, using measured FFR as the reference standard.
Time frame: June 2026 to December 2027
To establish the diagnostic performance of AngioAI+ System
Description: 2. Diagnostic performance (i.e., sensitivity and specificity) of AngioAI+ for detecting CMD in patients with non-obstructive CAD using invasive coronary flow reserve (CFR) derived from continuous thermodilution as reference.
Time frame: June 2026 to December 2027
Plan to share: Undecided — Decision regarding IPD sharing will be made in the future.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.